Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. Until today this year the stock’s price performance recorded a decrease of -55.64%. However, over the last six months, the performance has been stronger by -58.21%. The price of HUMA increased 44.52% over the last 30 days. And in the last five days, it has surged by 88.24%.
The market performance of Humacyte Inc’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $9.97 on 05/31/24, while the lowest value for the same duration was $1.15 on 04/08/25.
52-week price history of HUMA Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Humacyte Inc’s current trading price is -77.53% away from its 52-week high, while its distance from the 52-week low is 94.78%. The stock’s price range during this time has been between $1.15 and $9.97. The trading volume for the Healthcare sector company’s shares reached about 6.86 million for the day, which was higher than the average daily volume of 4.16 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Humacyte Inc (HUMA) has experienced a quarterly decline of -42.71% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 347.47M and boasts a workforce of 220 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.08, with a change in price of -1.22. Similarly, Humacyte Inc recorded 4,535,371 in trading volume during the last 100 days, posting a change of -35.26%.
HUMA’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for HUMA stands at 2.28. Similarly, the long-term debt-to-equity ratio is also 2.15.
HUMA Stock Stochastic Average
Today, Humacyte Inc’s raw stochastic average for the past 50 days stands at 49.32%, indicating a decline from the raw stochastic average of the last 20 days, which was 98.15%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 86.67% and 78.44% respectively.
